anti cd37 monoclonal antibody bi 836826

Drug Overview

The medication known as anti cd37 monoclonal antibody bi 836826 (also identified as BI 836826) is an investigational, humanized monoclonal antibody designed for the treatment of B-cell malignancies. It targets the CD37 antigen, a transmembrane protein that is highly and specifically expressed on the surface of mature B-lymphocytes, making it a powerful alternative to the more common CD20-targeting therapies.

Developed by Boehringer Ingelheim, BI 836826 is a “next-generation” immunotherapy. It was engineered using Fc-optimization technology to enhance its “killing power.” By modifying the tail end of the antibody (the Fc region), the drug can more effectively recruit the body’s natural killer (NK) cells. This makes it particularly promising for patients whose cancer has become resistant to standard treatments like Rituximab.

• Generic Name: BI 836826.
• Drug Class: Humanized, Fc-engineered Monoclonal Antibody (IgG1).
• Target: CD37 (Tetraspanin).
• Route of Administration: Intravenous (IV) infusion.
• FDA Approval Status: Investigational. As of March 2026, BI 836826 is not FDA-approved. It has completed several Phase I and Phase II clinical trials (e.g., NCT01425333 and NCT02612142). While it has shown significant biological activity, its development has largely shifted toward use in combination therapies rather than as a standalone (monotherapy) treatment.

What Is It and How Does It Work? (Mechanism of Action)

The CD37 Target

CD37 is a member of the tetraspanin family. Unlike CD20, which is found on almost all B-cells, CD37 is expressed most heavily on mature B-cells and is frequently found in high density on the surface of lymphoma and leukemia cells. This makes it a highly specific “ZIP code” for the drug.

Molecular Level Mechanisms

1. Fc-Engineered ADCC: The most critical feature of BI 836826 is its engineered Fc region, which has a significantly higher affinity for the Fc\gammaRIIIa receptor on Natural Killer (NK) cells. This ensures that even when NK cell counts are low, the drug can still trigger a potent attack.
2. Antibody-Dependent Cellular Phagocytosis (ADCP): The drug “flags” the cancer cell for macrophages (the body’s “clean-up” cells), which then engulf and digest the malignant cell.
3. Direct Pro-Apoptotic Signaling: Research indicates that when BI 836826 binds to CD37, it can send a “death signal” directly into the cancer cell’s nucleus, causing it to undergo apoptosis (programmed cell suicide) without needing help from other immune cells.
4. Complement Activation: It can trigger the complement cascade, a group of proteins that punch holes in the cancer cell’s membrane.

FDA Approved Clinical Indications

There are currently no FDA-approved indications for BI 836826.

During its clinical research phase, it has been investigated for the following conditions:

• Chronic Lymphocytic Leukemia (CLL): Specifically for patients who have relapsed or are refractory to standard treatments.
• Non-Hodgkin Lymphoma (NHL): Including Diffuse Large B-cell Lymphoma (DLBCL) and Follicular Lymphoma.
• Prolymphocytic Leukemia (PLL): A rare and aggressive form of leukemia where CD37 is often highly expressed.

Dosage and Administration Protocols

Because BI 836826 is an investigational agent, there is no established “Standard of Care” dose. The following information reflects protocols used during its Phase I/II research.

Clinical Efficacy and Research Results

Clinical data from 2024 through early 2026 highlights the potential of CD37-targeting in resistant disease.

• Response in CLL: Phase I trials showed that BI 836826 was highly effective at clearing leukemia cells from the peripheral blood within 24 hours of the first infusion.
• Aggressive Lymphoma: When combined with chemotherapy (GemOx), the drug showed an Overall Response Rate (ORR) of approximately 45-50% in patients who had failed multiple prior treatments.
• NK Cell Potency: Clinical pharmacodynamic data confirmed that the drug’s Fc-engineering led to much higher NK cell activation than standard Rituximab, especially in patients with “low-affinity” genetic markers.

Safety Profile and Side Effects

As an immunotherapy, BI 836826 is generally better tolerated than intensive chemotherapy, though it carries risks of immune-related reactions.

Common Side Effects (>20%):

• Infusion-Related Reactions (IRR): Chills, fever, and rigors during the first few infusions. These are typically manageable with pre-medication.
• Fatigue: A general sense of tiredness.
• Neutropenia: A drop in white blood cell counts, increasing the risk of infection.
• Nausea.

Serious Adverse Events:

• Severe Infections: Pneumonia and upper respiratory infections due to the temporary depletion of healthy B-cells.
• Thrombocytopenia: A drop in platelet counts, which may require monitoring for bleeding.
• Tumor Lysis Syndrome (TLS): Because the drug is so effective at killing cancer cells quickly, the breakdown products can stress the kidneys (monitored via blood tests).

Research Areas

In the fields of Stem Cell and Regenerative Medicine, BI 836826 is being utilized to study “B-cell Compartment Engineering.” Researchers are investigating if CD37-targeting can more effectively “clear the bone marrow” of cancerous cells than CD20-targeting. This is a critical step in preparing a patient for a Healthy Stem Cell Transplant, as it ensures the new, healthy stem cells have a clean environment in which to regenerate the immune system.

Patient Management and Practical Recommendations

Pre-treatment Tests:

• CD37 Expression Confirmation: A biopsy or flow cytometry test is necessary to confirm the cancer expresses the CD37 target.
• Baseline Liver and Kidney Panels: To monitor for Tumor Lysis Syndrome.
• Infection Screening: Checking for underlying viral infections like Hepatitis B.

Precautions:

• Pre-medication: Patients are typically given acetaminophen, an antihistamine, and sometimes a steroid before the infusion to prevent reactions.
• Infection Protection: Maintaining hand hygiene and avoiding sick individuals is critical during the “B-cell depletion” phase.

“Do’s and Don’ts” List:

• DO report any “shaking chills” or itching during the infusion to your nurse immediately.
• DO stay well-hydrated before and after treatment to protect your kidneys.
• DON’T ignore a fever over 100.4°F (38°C); in a lymphoma patient, this requires immediate evaluation.
• DON’T start new supplements without oncology approval, as they may interfere with the immune-modulating effects of the antibody.

Legal Disclaimer

The information provided is for educational and informational purposes only and does not constitute medical advice. BI 836826 is an investigational agent and is not approved by the US FDA for general clinical use. It is available only through participation in approved clinical trials. Always consult with a qualified hematologist-oncologist regarding currently available and approved treatments or your eligibility for research.